SG11201600048VA - Novel fused pyrimidine compound or salt thereof - Google Patents

Novel fused pyrimidine compound or salt thereof

Info

Publication number
SG11201600048VA
SG11201600048VA SG11201600048VA SG11201600048VA SG11201600048VA SG 11201600048V A SG11201600048V A SG 11201600048VA SG 11201600048V A SG11201600048V A SG 11201600048VA SG 11201600048V A SG11201600048V A SG 11201600048VA SG 11201600048V A SG11201600048V A SG 11201600048VA
Authority
SG
Singapore
Prior art keywords
salt
pyrimidine compound
fused pyrimidine
novel fused
novel
Prior art date
Application number
SG11201600048VA
Inventor
Satoru Iguchi
Fumihito Hosoi
Takeshi Sagara
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of SG11201600048VA publication Critical patent/SG11201600048VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02Boron compounds
SG11201600048VA 2013-08-12 2014-08-11 Novel fused pyrimidine compound or salt thereof SG11201600048VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013167600 2013-08-12
PCT/JP2014/071158 WO2015022926A1 (en) 2013-08-12 2014-08-11 Novel fused pyrimidine compound or salt thereof

Publications (1)

Publication Number Publication Date
SG11201600048VA true SG11201600048VA (en) 2016-03-30

Family

ID=52468312

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201600048VA SG11201600048VA (en) 2013-08-12 2014-08-11 Novel fused pyrimidine compound or salt thereof

Country Status (23)

Country Link
US (1) US9580432B2 (en)
EP (1) EP2947086B1 (en)
JP (1) JP6035423B2 (en)
KR (1) KR101828187B1 (en)
CN (1) CN105452257B (en)
AU (1) AU2014307437B2 (en)
BR (1) BR112016002069B1 (en)
CA (1) CA2921208C (en)
DK (1) DK2947086T3 (en)
ES (1) ES2661733T3 (en)
HK (1) HK1217703A1 (en)
HU (1) HUE036834T2 (en)
MX (1) MX360498B (en)
MY (1) MY171831A (en)
NO (1) NO2947086T3 (en)
PH (1) PH12015502737A1 (en)
PL (1) PL2947086T3 (en)
PT (1) PT2947086T (en)
RU (1) RU2666349C2 (en)
SG (1) SG11201600048VA (en)
TR (1) TR201802875T4 (en)
TW (1) TWI585089B (en)
WO (1) WO2015022926A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201908045VA (en) 2013-08-23 2019-10-30 Neupharma Inc Certain chemical entities, compositions, and methods
SG11201704430SA (en) 2015-01-30 2017-08-30 Taiho Pharmaceutical Co Ltd Preventive and/or therapeutic agent of immune disease
ES2667247T3 (en) 2015-01-30 2018-05-10 Taiho Pharmaceutical Co., Ltd. Novel salt of condensed pyrimidine compound and crystal thereof
KR102075886B1 (en) * 2015-09-01 2020-02-11 다이호야쿠힌고교 가부시키가이샤 Novel pyrazolo [3,4-d] pyrimidine compounds or salts thereof
MA41559A (en) * 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd CONDENSED PYRIMIDINE COMPOUND OR A SALT THEREOF
US9834561B2 (en) * 2015-10-28 2017-12-05 Scinopharm Taiwan, Ltd. Process for preparing ibrutinib and its intermediates
MD3269370T2 (en) 2016-02-23 2020-05-31 Taiho Pharmaceutical Co Ltd Novel condensed pyrimidine compound or salt thereof
CA3033370A1 (en) * 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2018159613A1 (en) * 2017-02-28 2018-09-07 大鵬薬品工業株式会社 Antitumor-effect enhancer using pyrazolo[3,4-d]pyrimidine compound
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
EP4079306A4 (en) 2019-12-19 2024-01-10 Taiho Pharmaceutical Co Ltd Therapeutic agent containing fused pyrimidine compound as active ingredient
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20230031926A (en) * 2020-07-15 2023-03-07 다이호야쿠힌고교 가부시키가이샤 Combinations comprising pyrimidine compounds for use in the treatment of tumors
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN114736207B (en) * 2022-04-28 2023-03-31 武汉九州钰民医药科技有限公司 Preparation process of small molecule HER2 inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157434B2 (en) 2003-10-27 2007-01-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
CN101336244B (en) * 2005-12-08 2011-11-30 雅培制药有限公司 9-membered heterobicyclic compounds as inhibitors of protein kinases
BRPI0709699A2 (en) 2006-03-29 2011-07-26 Foldrx Pharmaceuticals Inc inhibition of alpha synuclein toxicity
WO2008121742A2 (en) 2007-03-28 2008-10-09 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2008054827A2 (en) * 2006-11-03 2008-05-08 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
WO2009057733A1 (en) 2007-10-31 2009-05-07 Santen Pharmaceutical Co., Ltd. Novel indole derivative having anti-angiogenic activity
DK2361248T3 (en) 2008-06-27 2019-01-14 Celgene Car Llc Heteroberl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EA201490265A1 (en) * 2011-07-13 2014-12-30 Фармасайкликс, Инк. BLUTON TYROSINKINASE INHIBITORS
EP2731651B1 (en) * 2011-07-15 2020-03-11 Sanofi-Aventis Deutschland GmbH A drug delivery device
MY171055A (en) 2012-01-19 2019-09-23 Taiho Pharmaceutical Co Ltd 3,5-disubstituted alkynylbenzene compound and salt thereof
CN104250250A (en) * 2013-06-25 2014-12-31 苏州科捷生物医药有限公司 4-aromatic aminopyrimidine compound and anti-tumor use thereof

Also Published As

Publication number Publication date
PT2947086T (en) 2018-03-09
HUE036834T2 (en) 2018-08-28
CA2921208A1 (en) 2015-02-19
KR20160038891A (en) 2016-04-07
NO2947086T3 (en) 2018-06-02
JPWO2015022926A1 (en) 2017-03-02
MY171831A (en) 2019-11-01
HK1217703A1 (en) 2017-01-20
EP2947086A1 (en) 2015-11-25
EP2947086A4 (en) 2016-06-22
TWI585089B (en) 2017-06-01
PH12015502737B1 (en) 2016-03-07
US9580432B2 (en) 2017-02-28
CN105452257B (en) 2017-09-05
DK2947086T3 (en) 2018-03-19
RU2015156524A (en) 2017-09-14
JP6035423B2 (en) 2016-11-30
AU2014307437A1 (en) 2016-01-21
KR101828187B1 (en) 2018-02-09
AU2014307437B2 (en) 2016-12-15
MX2016001845A (en) 2016-05-16
PL2947086T3 (en) 2018-06-29
BR112016002069B1 (en) 2020-08-18
CA2921208C (en) 2018-02-20
BR112016002069A2 (en) 2017-08-01
CN105452257A (en) 2016-03-30
TW201536786A (en) 2015-10-01
TR201802875T4 (en) 2018-03-21
PH12015502737A1 (en) 2016-03-07
WO2015022926A1 (en) 2015-02-19
MX360498B (en) 2018-11-05
RU2666349C2 (en) 2018-09-07
US20160115168A1 (en) 2016-04-28
ES2661733T3 (en) 2018-04-03
EP2947086B1 (en) 2018-01-03

Similar Documents

Publication Publication Date Title
HK1252317A1 (en) Novel amino pyrimidine derivatives
HK1217703A1 (en) Novel fused pyrimidine compound or salt thereof
IL257306B (en) Fused pyrimidine compound or salt thereof
GB201303109D0 (en) Novel pyrimidine compounds
EP2982666A4 (en) Heterocyclic compound
HK1221465A1 (en) Novel heterocyclic compounds
EP3018126A4 (en) Heterocyclic compound
ZA201506296B (en) 2-acylaminothiazole derivative or salt thereof
EP2980089A4 (en) Heterocyclic compound
PL2986600T3 (en) Substituted condensed pyrimidine compounds
HRP20190133T1 (en) Heterocyclic compound
EP2982670A4 (en) Heterocyclic compound
HUE035967T2 (en) Novel substituted condensed pyrimidine compounds
IL245452B (en) Aramchol salt